Fate Therapeutics Inc
0.00 (0.00%)


Draw Mode:

Volume 0
Bid Price 5.15
Ask Price 5.61
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Fate Therapeutics Inc FATE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 5.15 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 4.02 - 43.12
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 5.15 USD

Fate Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 505.53M 98.16M 73.67M $ 96.30M $ - -2.91 -1.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 2.62M 1.80%

more financials information »

Fate Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No FATE Message Board. Create One! See More Posts on FATE Message Board See More Message Board Posts

Historical FATE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.535.665.135.505,339,185-0.38-6.87%
1 Month6.376.98854.785.633,365,108-1.22-19.15%
3 Months10.0111.43994.026.294,129,463-4.86-48.55%
6 Months22.1423.964.029.832,762,259-16.99-76.74%
1 Year37.3543.124.0216.282,118,253-32.20-86.21%
3 Years22.72121.164.0237.851,406,085-17.57-77.33%
5 Years10.93121.164.0232.511,141,635-5.78-52.88%

Fate Therapeutics Description

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.